News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
PRENDERGAST FRANKLYN G
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 60,840 shares
@ $0
Granted 137,725 options to buy
@ $1.35, valued at
$185.9k
|
|
| 06/12/2023 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 6,500 options to buy
@ $4.84, valued at
$31.5k
|
|
| 09/12/2022 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on NeuBase Therapeutics, Inc.|
Txns:
| Granted 37,600 options to buy
@ $0.6, valued at
$22.6k
|
|
| 06/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/08/2021 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on Lantern Pharma Inc.|
Txns:
| Granted 3,200 options to buy
@ $10.32, valued at
$33k
|
|
| 09/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/21/2021 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on Immunome Inc.|
Txns:
| Granted 7,500 options to buy
@ $16.96, valued at
$127.2k
|
|
| 06/21/2021 |
3
| PRENDERGAST FRANKLYN G (Director) has filed a Form 3 on Immunome Inc. |
| 09/11/2020 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on NeuBase Therapeutics, Inc.|
Txns:
| Granted 14,634 options to buy
@ $8.8, valued at
$128.8k
|
|
| 06/15/2020 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on Lantern Pharma Inc.|
Txns:
| Granted 9,135 options
@ $0 |
|
| 06/10/2020 |
3
| PRENDERGAST FRANKLYN G (Director) has filed a Form 3 on Lantern Pharma Inc. |
| 08/21/2019 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on CANCER GENETICS, INC|
Txns:
| Granted 100,000 options to buy
@ $0.15, valued at
$15k
|
|
| 07/16/2019 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on NeuBase Therapeutics, Inc.|
Txns:
| Granted 227,330 options to buy
@ $5.39, valued at
$1.2M
|
|
| 07/16/2019 |
3
| PRENDERGAST FRANKLYN G (Director) has filed a Form 3 on NeuBase Therapeutics, Inc. |
| 11/22/2017 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on LILLY ELI & CO|
Txns:
| Granted 802 shares
@ $83.18, valued at
$66.7k
|
|
| 10/02/2017 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on CANCER GENETICS, INC|
Txns:
| Granted 2,500 shares
@ $0
Granted 5,000 options to buy
@ $2.75, valued at
$13.8k
|
|
| 06/08/2017 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on CANCER GENETICS, INC|
Txns:
| Granted 2,500 shares
@ $0
Granted 10,000 options to buy
@ $4.15, valued at
$41.5k
|
|
| 12/01/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 10/13/2016 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on CANCER GENETICS, INC |
| 12/02/2015 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 05/18/2015 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on CANCER GENETICS, INC|
Txns:
| Granted 10,000 options to buy
@ $10.74, valued at
$107.4k
|
|
| 12/02/2014 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on LILLY ELI & CO|
Txns:
| Granted 2,155 shares
@ $67.29, valued at
$145k
|
|
| 06/11/2014 |
4/A
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on CANCER GENETICS, INC|
Txns:
| Granted 10,000 options to buy
@ $11.7, valued at
$117k
|
|
| 05/27/2014 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on CANCER GENETICS, INC|
Txns:
| Granted 5,000 shares
@ $0 |
|
| 12/03/2013 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 10/15/2013 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on CANCER GENETICS, INC |
| 12/03/2012 |
4
| PRENDERGAST FRANKLYN G (Director) has filed a Form 4 on LILLY ELI & CO|
Txns:
| Granted 3,083 shares
@ $47.03, valued at
$145k
|
|
| 12/01/2011 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 12/01/2010 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 12/01/2009 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
|
|